273 research outputs found
Detección morfológica de la podredumbre carbonosa en soja y maíz en Misiones, Argentina
Introducción. La podredumbre carbonosa causada por Macrophomina phaseolina es un patógeno que sobrevive en el suelo mediante microesclerocios (fase de Sclerotium bataticola). Este patógeno afecta a diferentes cultivos, entre los que se destancan la soja (Glycine max L. Merrill) y el maíz (Zea mays L.), por su importancia en la Argentina. Objetivo. Demostrar que el causante de las muertes de las plantas de soja y de maíz en los años de sequía en la provincia de Misiones es la prodredumbre carbonosa. Materiales y métodos. Se recolectaron muestras de diferentes localidades de la provincia de Misiones, Argentina, durante febrero de 2022. Mediante la observación a ojo desnudo de plantas enfermas y con el auxilio de microscopia estereoscópica y microscoscopio óptico se determinó la identidad del patógeno presente. Resultados. Se detectó la presencia de microesclerocios compatibles con S. bataticola como agente causal de podredumbre carbonosa en las muestras de maíz y soja, en todas las muestras de la provincia de Misiones. Conclusión. La podredumbre carbonosa causada por M. phaseolina se encuentra presente en los cultivos de soja y de maíz en la provincia de Misiones, Argentina.
Emergence of quinolone resistance among extended-spectrum beta-lactamase-producing Enterobacteriaceae in the Central African Republic: genetic characterization
<p>Abstract</p> <p>Background</p> <p>Cross-resistance to quinolones and beta-lactams is frequent in <it>Enterobacteriaceae</it>, due to the wide use of these antibiotics clinically and in the food industry. Prescription of one of these categories of antibiotic may consequently select for bacteria resistant to both categories. Genetic mechanisms of resistance may be secondary to a chromosomal mutation located in quinolone resistance determining region of DNA gyrase or topoisomerase IV or to a plasmid acquisition. The insertion sequence IS<it>CR1 </it>is often associated with <it>qnr </it>and may favour its dissemination in Gram-negative bacteria. The aim of this study was to determine the genetic mechanism of quinolone resistance among extended-spectrum beta-lactamase-producing <it>Enterobacteriaceae </it>strains in the Central African Republic.</p> <p>Findings</p> <p>Among seventeen ESBL-producing <it>Enterobacteriaceae </it>isolated from urine, pus or stool between January 2003 and October 2005 in the Central African Republic, nine were resistant to ciprofloxacin (seven from community patients and two from hospitalized patients). The ESBL were previously characterized as CTX-M-15 and SHV-12. Susceptibility to nalidixic acid, norfloxacin and ciprofloxacin, and the minimal inhibitory concentrations of these drugs were determined by disc diffusion and agar dilution methods, respectively. The presence of plasmid-borne IS<it>CR1-qnrA </it>region was determined by PCR and amplicons, if any, were sent for sequencing. Quinolone resistance determining region of DNA gyrase <it>gyrA </it>gene was amplified by PCR and then sequenced for mutation characterization. We found that all CTX-M-producing strains were resistant to the tested quinolones. All the isolates had the same nucleotide mutation at codon 83 of <it>gyrA</it>. Two <it>Escherichia coli </it>strains with the highest MICs were shown to harbour an IS<it>CR1-qnrA1 </it>sequence. This genetic association might favour dissemination of resistance to quinolone and perhaps other antibiotics among <it>Enterobacteriaceae</it>.</p> <p>Conclusions</p> <p>This study shows that at least two mechanisms might explain the emerging resistance of <it>Enterobacteriaceae </it>to quinolones in the CAR. Beside the classical topoisomerase mutation, the cause may be acquisition of a plasmid-borne <it>qnrA1</it>. Clinicians and bacteriologists should be made aware of possible dissemination of IS<it>CR1-qnrA1 </it>among <it>Enterobacteriacae</it>.</p
A Nonluminescent and Highly Virulent Vibrio harveyi Strain Is Associated with “Bacterial White Tail Disease” of Litopenaeus vannamei Shrimp
Recurrent outbreaks of a disease in pond-cultured juvenile and subadult Litopenaeus vannamei shrimp in several districts in China remain an important problem in recent years. The disease was characterized by “white tail” and generally accompanied by mass mortalities. Based on data from the microscopical analyses, PCR detection and 16S rRNA sequencing, a new Vibrio harveyi strain (designated as strain HLB0905) was identified as the etiologic pathogen. The bacterial isolation and challenge tests demonstrated that the HLB0905 strain was nonluminescent but highly virulent. It could cause mass mortality in affected shrimp during a short time period with a low dose of infection. Meanwhile, the histopathological and electron microscopical analysis both showed that the HLB0905 strain could cause severe fiber cell damages and striated muscle necrosis by accumulating in the tail muscle of L. vannamei shrimp, which led the affected shrimp to exhibit white or opaque lesions in the tail. The typical sign was closely similar to that caused by infectious myonecrosis (IMN), white tail disease (WTD) or penaeid white tail disease (PWTD). To differentiate from such diseases as with a sign of “white tail” but of non-bacterial origin, the present disease was named as “bacterial white tail disease (BWTD)”. Present study revealed that, just like IMN and WTD, BWTD could also cause mass mortalities in pond-cultured shrimp. These results suggested that some bacterial strains are changing themselves from secondary to primary pathogens by enhancing their virulence in current shrimp aquaculture system
Clinical outcomes of temporary mechanical circulatory support as a direct bridge to heart transplantation: a nationwide Spanish registry
Background: In Spain, listing for high-urgent heart transplantation is allowed for critically ill candidates not weanable from temporary mechanical circulatory support (T-MCS). We sought to analyse the clinical outcomes of this strategy.
Methods and results: We conducted a case-by-case, retrospective review of clinical records of 291 adult patients listed for high-urgent heart transplantation under temporary devices from 2010 to 2015 in 16 Spanish institutions. Survival after listing and adverse clinical events were studied. At the time of listing, 169 (58%) patients were supported on veno-arterial extracorporeal membrane oxygenation (VA-ECMO), 70 (24%) on temporary left ventricular assist devices (T-LVAD) and 52 (18%) on temporary biventricular assist devices (T-BiVAD). Seven patients transitioned from VA-ECMO to temporary ventricular assist devices while on the waiting list. Mean time on T-MCS was 13.1 ± 12.6 days. Mean time from listing to transplantation was 7.6 ± 8.5 days. Overall, 230 (79%) patients were transplanted and 54 (18.6%) died during MCS. In-hospital postoperative mortality after transplantation was 33.3%, 11.9% and 26.2% for patients bridged on VA-ECMO, T-LVAD and T-BiVAD, respectively (P = 0.008). Overall survival from listing to hospital discharge was 54.4%, 78.6% and 55.8%, respectively (P = 0.002). T-LVAD support was independently associated with a lower risk of death over the first year after listing (hazard ratio 0.52, 95% confidence interval 0.30–0.92). Patients treated with VA-ECMO showed the highest incidence rate of adverse clinical events associated with T-MCS.
Conclusion: Temporary devices may be used to bridge critically ill candidates directly to heart transplantation in a setting of short waiting list times, as is the case of Spain. In our series, bridging with T-LVAD was associated with more favourable outcomes than bridging with T-BiVAD or VA-ECMO
Prognosis and serum creatinine levels in acute renal failure at the time of nephrology consultation: an observational cohort study
The aim of this study is to evaluate the association between acute
serum creatinine changes in acute renal failure (ARF), before specialized
treatment begins, and in-hospital mortality, recovery of renal function, and
overall mortality at 6 months, on an equal degree of ARF severity, using the
RIFLE criteria, and comorbid illnesses. METHODS: Prospective cohort study of 1008
consecutive patients who had been diagnosed as having ARF, and had been admitted
in an university-affiliated hospital over 10 years. Demographic, clinical
information and outcomes were measured. After that, 646 patients who had
presented enough increment in serum creatinine to qualify for the RIFLE criteria
were included for subsequent analysis. The population was divided into two groups
using the median serum creatinine change (101%) as the cut-off value.
Multivariate non-conditional logistic and linear regression models were used.
RESULTS: A >or= 101% increment of creatinine respect to its baseline before
nephrology consultation was associated with significant increase of in-hospital
mortality (35.6% vs. 22.6%, p < 0.001), with an adjusted odds ratio of 1.81 (95%
CI: 1.08-3.03). Patients who required continuous renal replacement therapy in the
>or= 101% increment group presented a higher increase of in-hospital mortality
(62.7% vs 46.4%, p = 0.048), with an adjusted odds ratio of 2.66 (95% CI:
1.00-7.21). Patients in the >or= 101% increment group had a higher mean serum
creatinine level with respect to their baseline level (114.72% vs. 37.96%) at
hospital discharge. This was an adjusted 48.92% (95% CI: 13.05-84.79) more serum
creatinine than in the < 101% increment group. CONCLUSION: In this cohort,
patients who had presented an increment in serum level of creatinine of >or= 101%
with respect to basal values, at the time of nephrology consultation, had
increased mortality rates and were discharged from hospital with a more
deteriorated renal function than those with similar Liano scoring and the same
RIFLE classes, but with a < 101% increment. This finding may provide more
information about the factors involved in the prognosis of ARF. Furthermore, the
calculation of relative serum creatinine increase could be used as a practical
tool to identify those patients at risk, and that would benefit from an intensive
therapy
Burden and challenges of heart failure in patients with chronic kidney disease. A call to action
Patients with the dual burden of chronic kidney disease (CKD) and chronic congestive heart
failure (HF) experience unacceptably high rates of symptom load, hospitalization, and mortality. Currently, concerted efforts to identify, prevent and treat HF in CKD patients are
lacking at the institutional level, with emphasis still being placed on individual specialty
views on this topic. The authors of this review paper endorse the need for a dedicated
cardiorenal interdisciplinary team that includes nephrologists and renal nurses and jointly manages appropriate clinical interventions across the inpatient and outpatient settings.
There is a critical need for guidelines and best clinical practice models from major cardiology
and nephrology professional societies, as well as for research funding in both specialties to
focus on the needs of future therapies for HF in CKD patients. The implementation of crossspecialty educational programs across all levels in cardiology and nephrology will help train
future specialists and nurses who have the ability to diagnose, treat, and prevent HF in CKD
patients in a precise, clinically effective, and cost-favorable manner.Los pacientes con enfermedad renal crónica (ERC) que desarrollan insuficiencia cardíaca (IC)
congestiva crónica presentan cifras inaceptablemente altas de síntomas, hospitalización y
mortalidad. Actualmente, se echan en falta iniciativas institucionales dirigidas a identificar,
prevenir y tratar la IC en los pacientes con ERC de manera multidisciplinar, prevaleciendo
las actuaciones de las especialidades individuales. Los autores de este artículo de revisión
respaldan la necesidad de crear equipos multidisciplinares cardiorrenales, en los que participen nefrólogos y enfermeras renales, que gestionen colaborativamente las intervenciones
clínicas apropiadas en los entornos de pacientes con ERC e IC hospitalizados y ambulatorios.
Es necesario y urgente que se elaboren guías y modelos de práctica clínica sobre la ERC con IC
por parte de las sociedades profesionales de cardiología y nefrología, así como financiación
para la investigación concertada entre ambas especialidades sobre la necesidad de futuros
tratamientos para la IC en pacientes con ERC. La implementación de programas educativos
cardiorrenales a todos los niveles en cardiología y nefrología ayudará a formar a los futuros
especialistas y enfermeras para que tengan la capacidad de diagnosticar, tratar y prevenir
la IC en pacientes con ERC de manera precisa, clínicamente efectiva y económicamente
favorabl
A precision medicine test predicts clinical response after idarubicin and cytarabine induction therapy in AML patients
Complete remission (CR) after induction therapy is the first treatment goal in acute myeloid leukemia (AML) patients and has prognostic impact. Our purpose is to determine the correlation between the observed CR/CRi rate after idarubicin (IDA) and cytarabine (CYT) 3 + 7 induction and the leukemic chemosensitivity measured by an ex vivo test of drug activity. Bone marrow samples from adult patients with newly diagnosed AML were included in this study. Whole bone marrow samples were incubated for 48 h in well plates containing IDA, CYT, or their combination. Pharmacological response parameters were estimated using population pharmacodynamic models. Patients attaining a CR/CRi with up to two induction cycles of 3 + 7 were classified as responders and the remaining as resistant. A total of 123 patients fulfilled the inclusion criteria and were evaluable for correlation analyses. The strongest clinical predictors were the area under the curve of the concentration response curves of CYT and IDA. The overall accuracy achieved using MaxSpSe criteria to define positivity was 81%, predicting better responder (93%) than non-responder patients (60%). The ex vivo test provides better yet similar information than cytogenetics, but can be provided before treatment representing a valuable in-time addition. After validation in an external cohort, this novel ex vivo test could be useful to select AML patients for 3 + 7 regimen vs. alternative schedules
Vaccinia virus-mediated intra-tumoral expression of matrix metalloproteinase 9 enhances oncolysis of PC-3 xenograft tumors
A precision medicine test predicts clinical response after idarubicin and cytarabine induction therapy in AML patients
Complete remission (CR) after induction therapy is the first treatment goal in acute myeloid leukemia (AML) patients and has prognostic impact. Our purpose is to determine the correlation between the observed CR/CRi rate after idarubicin (IDA) and cytarabine (CYT) 3 + 7 induction and the leukemic chemosensitivity measured by an ex vivo test of drug activity. Bone marrow samples from adult patients with newly diagnosed AML were included in this study. Whole bone marrow samples were incubated for 48 h in well plates containing IDA, CYT, or their combination. Pharmacological response parameters were estimated using population pharmacodynamic models. Patients attaining a CR/CRi with up to two induction cycles of 3 + 7 were classified as responders and the remaining as resistant. A total of 123 patients fulfilled the inclusion criteria and were evaluable for correlation analyses. The strongest clinical predictors were the area under the curve of the concentration response curves of CYT and IDA. The overall accuracy achieved using MaxSpSe criteria to define positivity was 81%, predicting better responder (93%) than non-responder patients (60%). The ex vivo test provides better yet similar information than cytogenetics, but can be provided before treatment representing a valuable in-time addition. After validation in an external cohort, this novel ex vivo test could be useful to select AML patients for 3 + 7 regimen vs. alternative schedules
Extended-Spectrum-Beta-Lactamases, AmpC Beta-Lactamases and Plasmid Mediated Quinolone Resistance in Klebsiella spp. from Companion Animals in Italy
We report the genetic characterization of 15 Klebsiella pneumoniae (KP) and 4 isolates of K. oxytoca (KO) from clinical cases in dogs and cats and showing extended-spectrum cephalosporin (ESC) resistance. Extended spectrum beta-lactamase (ESBL) and AmpC genes, plasmid-mediated quinolone resistance (PMQR) and co-resistances were investigated. Among KP isolates, ST101 clone was predominant (8/15, 53%), followed by ST15 (4/15, 27%). ST11 and ST340, belonging to Clonal Complex (CC)11, were detected in 2012 (3/15, 20%). MLST on KP isolates corresponded well with PFGE results, with 11 different PFGE patterns observed, including two clusters of two (ST340) and four (ST101) indistinguishable isolates, respectively. All isolates harbored at least one ESBL or AmpC gene, all carried on transferable plasmids (IncR, IncFII, IncI1, IncN), and 16/19 were positive for PMQR genes (qnr family or aac(6')-Ib-cr). The most frequent ESBL was CTX-M-15 (11/19, 58%), detected in all KP ST101, in one KP ST15 and in both KP ST340. blaCTX-M-15 was carried on IncR plasmids in all but one KP isolate. All KP ST15 isolates harbored different ESC resistance genes and different plasmids, and presented the non-transferable blaSHV-28 gene, in association with blaCTX-M-15, blaCTX-M-1 (on IncR, or on IncN), blaSHV-2a (on IncR) or blaCMY-2 genes (on IncI1). KO isolates were positive for blaCTX-M-9 gene (on IncHI2), or for the blaSHV-12 and blaDHA-1 genes (on IncL/M). They were all positive for qnr genes, and one also for the aac(6')-Ib-cr gene. All Klebsiella isolates showed multiresistance towards aminoglycosides, sulfonamides, tetracyclines, trimethoprim and amphenicols, mediated by strA/B, aadA2, aadB, ant (2")-Ia, aac(6')-Ib, sul, tet, dfr and cat genes in various combinations. The emergence in pets of multidrug-resistant Klebsiella with ESBL, AmpC and PMQR determinants, poses further and serious challenges in companion animal therapy and raise concerns for possible bi-directional transmission between pets and humans, especially at household level
- …